Approval Year
| Substance Class |
Concept
|
| Record UNII |
SZ7226875S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SZ7226875S
Created by
admin on Sat Dec 16 19:16:30 GMT 2023 , Edited by admin on Sat Dec 16 19:16:30 GMT 2023
|
PRIMARY |
This is a non-substance concept
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
METABOLITE ACTIVE -> PRODRUG |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
TAK-186 is a prodrug that can bind to cell surface-expressed EGFR and circulating serum albumin. The binding to serum albumin extends the half-life of the prodrug form. Activation is achieved through tumor microenvironment (TME)-mediated proteolytic cleavage of an internal peptide linker, releasing an inactivating moiety that functionally restricts the molecule’s ability to stimulate T-cells through specific binding to the epsilon subunit of cluster of differentiation 3 (CD3ε; a member of the T-cell receptor complex).
|
This is a non-substance concept